10 Firms Defy Market Slump, Record Double-Digit Gains Last Week

2. Certara Inc. (NASDAQ:CERT)

Certara Inc. grew its share prices by 35.18 percent last week to finish at $12.91 each on Friday versus the $9.55 on April 4 following news that it released a new version of the Simcyp Simulator to support physiologically-based pharmacokinetic (PBPK) modeling, which can forecast the behavior of drugs in various body tissues.

According to CERT, the latest version would strengthen its position as a leader in the PBPK modeling in drug development and regulatory decision-making.

In the fourth quarter of 2024, CERT swung to a net income of $6.6 million from a net loss of $12.5 million in the same period a year earlier. Revenues increased by 14 percent to $100.4 million from $88 million year-on-year.

For this year, CERT expects revenues to settle between $415 million and $425 million as well as earnings per share of $0.42 to $0.46 each.

CERT accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.